CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: Report from randomized phase III children’s oncology group trial AAML0531
Jatinder K. Lamba, Lata Chauhan, Miyoung Shin, Michael R. Loken, Jessica A. Pollard, Yi Cheng Wang, Rhonda E. Ries, Richard Aplenc, Betsy A. Hirsch, Susana C. Raimondi, Roland B. Walter, Irwin D. Bernstein, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi
Dive into the research topics of 'CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: Report from randomized phase III children’s oncology group trial AAML0531'. Together they form a unique fingerprint.